Case Report
A Case of TAFRO Syndrome Developed after COVID-19 Vaccination
Table 2
Analysis of pleural effusion and ascites.
| | Pleural effusions | Reference range |
| | sIL2-R (IU/mL) | 2130 | (157∼474) | | IgG (mg/dL) | 371 | (870∼1700) | | IgA (mg/dL) | 78 | (110∼410) | | IgM (mg/dL) | 12 | (33∼190) | | IL-6 (pg/mL) | 707 | (0∼4) | | VEGF (pg/mL) | 83 | (0∼38.3) | | CEA (ng/mL) | <0.5 | (0∼5) |
| | Ascites | | sIL2-R (IU/mL) | 1580 | (157∼474) | | IgG (mg/dL) | 247 | (870∼1700) | | IgA (mg/dL) | 49 | (110∼410) | | IgM (mg/dL) | 7 | (33∼190) | | IL-6 (pg/mL) | 249 | (0∼4) | | VEGF (pg/mL) | 129 | (0∼38.3) | | CEA (ng/mL) | <0.5 | (0∼5) |
|
|
sIL2-R; serum soluble interleukin-2 receptor, IgG; immunoglobulin G, IgA; immunoglobulin A, IgM; immunoglobulin M, IL-6; interleukin-6, VEGF; vascular endothelial growth factor, CEA; carcinoembryonic antigen.
|
